Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

The Canadian Bioceutical CBICF

MPX Bioceutical Corp is a Canada based company involved in the natural health products industry. It is engaged in the manufacture and distribution of nutraceuticals to the North American marketplace and providing financial and business expertise to emerging corporations primarily in the pharmaceutical, medical and biotechnology industries. The company provides management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to two medicinal cannab


GREY:CBICF - Post by User

Comment by Mike411Ontarioon Jan 05, 2019 7:44pm
144 Views
Post# 29190997

RE:Merger: Shareholders Should Receive More For MPX Bioceutical

RE:Merger: Shareholders Should Receive More For MPX Bioceutical
NEW YORK and TORONTO, Oct. 18, 2018 /PRNewswire/ - iAnthus Capital Holdings, Inc. ("iAnthus" or the "Company"), (CSE: IAN, OTCQX: ITHUF), and MPX Bioceutical Corporation ("MPX") (CSE: MPX; OTC:MPXEF) announced today that both companies have signed an arrangement agreement (the "Agreement") pursuant to which iAnthus will combine with MPX in an all-stock transaction with offered equity consideration to MPX shareholders valued at $835 million before giving effect to MPX International (defined below) and assuming all of MPX's dilutive securities are exercised prior to the completion of the transaction. The Agreement represents the first public to public merger transaction in U.S. cannabis history.
Read more at https://www.stockhouse.com/news/press-releases/2018/10/18/ianthus-and-mpx-bioceutical-announce-transformational-combination-expands-u-s#UPTxQkzPDWLRdF80.99
<< Previous
Bullboard Posts
Next >>